MedTrace Logo

Epicardial Ablation in Brugada Syndrome to Prevent Sudden Death

NCT03294278 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2023-09-29

No results posted yet for this study

Summary

A total of 150 patients will be randomized to perform catheter ablation or not in a 2:1 fashion in selected patients with Brugada-related symptoms (Ablation+ICD arm 105 patients vs ICD only 45 patients).

Conditions

  • Ventricular Arrhythmias and Cardiac Arrest

Interventions

OTHER

ablation plus ICD

Defibrillator, radio-frequency catheter ablation

Sponsors & Collaborators

  • IRCCS Policlinico S. Donato

    lead OTHER

Principal Investigators

  • Carlo Pappone, MD · IRCCS Policlinico San Donato Milan, Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-10
Primary Completion
2023-09-28
Completion
2023-12-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03294278 on ClinicalTrials.gov